전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved306 programs
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Anti-CD19 and anti-CD20 bicistronic CAR T- cells (Anti-CD19 and anti-CD20 bicistronic CAR T- cells)

Chronic Lymphocytic Leukemia; B-Cell Chronic Lymphocytic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleShenzhen Institute for Innovati…Phase 1

Anti-CD19-CAR transduced T cells (Anti-CD19-CAR transduced T cells)

Chronic Lymphocytic Leukemia; Acute Lymphocytic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Anti-CD19-chimeric-antigen-receptor-transduced T cells (Anti-CD19-chimeric-antigen-receptor-transduced T cells)

Leukemia, B-cell; Lymphoma, Hodgkins · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Active
CGTLimited DatastaleSumithira VasuPhase 1

Anti-CD19/CD20/CD22 CAR T-Cells (Anti-CD19/CD20/CD22 CAR T-Cells)

Recurrent Acute Lymphoblastic Leukemia; Recurrent B Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleSouthwest Hospital, ChinaPhase 2

Anti-CD20-CAR-transduced T cells (Anti-CD20-CAR-transduced T cells)

Leukemia; Lymphoma · CD20

#CD20#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleSouthwest Hospital, ChinaPhase 2

Anti-CD30-CAR-transduced T cells (Anti-CD30-CAR-transduced T cells)

Leukemia; Lymphoma · CD30

#CD30#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleSecond Affiliated Hospital, Sch…Phase 1

Anti-LILRA6 CAR-T cells (Anti-LILRA6 CAR-T cells)

Refractory Acute Myeloid Leukemia; Recurrent Acute Myeloid Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleAFA InsurancePhase 2

Autologous 3rd generation CD19-targeting CAR T cells (Autologous 3rd generation CD19-targeting CAR T cells)

B Cell Lymphoma; B Cell Leukemia · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleMayo ClinicPhase 1

Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563 (Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563)

Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Chronic Lymphocytic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleRoswell Park Cancer InstitutePhase 1

Autologous Anti-CD83 CAR T-cells (Autologous Anti-CD83 CAR T-cells)

Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleMayo ClinicPhase 1

Autologous BAFFR-targeting CAR T Cells (Autologous BAFFR-targeting CAR T Cells)

B-Cell Non-Hodgkin Lymphoma; Recurrent Chronic Lymphocytic Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous BCMA/CD19 dual-target CAR-T module (Autologous BCMA/CD19 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous BCMA/CD38 dual-target CAR-T module (Autologous BCMA/CD38 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous BCMA/GPRC5D dual-target CAR-T (Autologous BCMA/GPRC5D dual-target CAR-T)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleInstitute of Hematology and Blo…Phase 1

Autologous CAR123 T lymphocytes (Autologous CAR123 T lymphocytes)

Leukemia, Myeloid, Acute(AML); Precursor Cell Lymphoblastic Leukemia-Lymphoma · Leukemia, Myeloid, Acute(AML)

#LeukemiaMyeloidAcuteAML#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleMustang Bio, Inc.Phase 1

Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes (Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes)

Adult Acute Myeloid Leukemia in Remission; Acute Biphenotypic Leukemia · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleSeattle Children's HospitalPhase 1

Autologous CD19 CAR+ EGFTt + T cells (Autologous CD19 CAR+ EGFTt + T cells)

B Cell Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleHebei Senlang Biotechnology Inc…Phase 1

Autologous CD19-targeting CAR T cells (Autologous CD19-targeting CAR T cells)

Acute Lymphocytic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous CD19/CD20 dual-target CAR-T module (Autologous CD19/CD20 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous CD19/CD22 dual-target CAR-T module (Autologous CD19/CD22 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting

7 / 16 pages

← PreviousNext →